Monthly Round-Up of What to Read on Pharma Law and Policy
Bill of Health
NOVEMBER 17, 2022
Fulfillment of Postmarket Commitments and Requirements for New Drugs Approved by the FDA, 2013-2016. Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study. Limitations on the Capability of the FDA to Advise.
184 
Let's personalize your content